Novartis Oncology’s Post

1.2 to 1.5 million people are currently living with chronic myeloid leukemia (CML) worldwide. This new data may offer hope to those living with this difficult disease, advancing our mission to #reimaginemedicine for these patients. #ASCO24

Today we announce the FDA approval of a radioligand therapy for pediatric patients living with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first therapy specifically approved for pediatric patients with this rare cancer, and represents our ongoing commitment to developing the RLT platform across multiple cancer types and treatment settings. https://lnkd.in/e5mgsaBE

This #ENETS24 we're pleased to be presenting our encore data from the NETTER-2 trial exploring a radioligand therapy (#RLT) in a first-line setting for patients with grade 2 and grade 3 metastatic GEP-NETs.   Find more about the advancements in this space here: https://lnkd.in/ezStpJgw   #NeuroendocrineCancer

#NeuroendocrineTumors (#NETs) are rare types of cancers and the majority (over 60%) originate in the digestive system – these are called gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. The journey to diagnosis is often long and takes a toll on patients’ overall wellbeing. On average, it can take over four years from first onset of symptoms to a final diagnosis, after an extensive medical journey, including several examinations and multiple specialists. Unfortunately, such delays mean that the majority of patients are initially diagnosed with advanced disease. At Novartis, we are dedicated to discovering new ways to improve health outcomes for patient communities with clear unmet needs. Join us at the European Neuroendocrine Tumor Society e.V. (ENETS) congress to learn more about our commitment to exploring first-line treatment options for patients with grade 2 and grade 3 metastatic GEP-NETs. Learn more about #NeuroendocrineCancer during #ENETS24: http://ms.spr.ly/6043c91rP

GEP-NETs are a diverse and heterogeneous group of tumors with often vague and non-specific symptoms leading to delays in diagnosis. People diagnosed with this type of cancer often express somatostatin receptors on their tumor cells or tumor microenvironment. Radioligand therapy (#RLT) targets these receptors on cancer cells or tumor microenvironment, to destroy or damage them, with the goal of limiting impact on healthy tissues. Hear from us at the European Neuroendocrine Tumor Society e.V. (ENETS) congress as we present findings that explore the use of RLT as a potential first-line treatment in metastatic GEP-NETs. Learn more about radioligand therapies here: http://ms.spr.ly/6042c91Ru #ENETS24

Today at ASCO-GI, we announced the first set of Phase III data for a radioligand therapy (RLT) in the first-line setting. We’re proud to share the late-breaking results from the NETTER-2 trial https://lnkd.in/gXh7jvhd

What happens #BehindTheGlassAtNVS? At our #RadioligandTherapy (RLT) manufacturing facilities, highly specialized associates race against the clock every day as they seek to advance our mission to #ReimagineMedicine for the patients who need it. Learn more about the process—and what it means to the people at the heart of it. https://lnkd.in/gaWyq8TS

#RadioligandTherapy (RLT) manufacturing operates on a timeline of just hours and days. It’s an intricate process requiring not just precision but also urgency—enabling these medicines to reach the patients who need them. Go #BehindTheGlassAtNVS to see the process firsthand. https://lnkd.in/gBWQwdG4